ReviewWorld journal of microbiology & biotechnology2026
Engineering interventions for enhanced sophorolipid biosynthesis: from native producers to recombinant platforms.
Review in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sophorolipid (SL) are glycolipid biosurfactants with growing industrial relevance as sustainable alternatives to petrochemical surfactants. This review highlights the advances in SL genetics and pathway architecture, transcriptional and process level regulation, and comparative performance of native producers versus recombinant platforms. It emphasizes the transition from empirical optimization to rational, systems guided strategies integrating advance metabolic engineering strategies including pathway optimization to divert carbon flux toward the SL module, balance redox/energy demands with growth, and tailor congener profiles. We further evaluated the current industrial feasibility, technology used by several companies highlighting progress increasing titers and productivities alongside persistent constraints in production, reliance on costly feedstocks, different fermentation methods, process parameters, and challenging downstream recovery. Key research gaps include incomplete understanding of regulatory control, limited systematic flux redistribution, and insufficient techno-economic integration. We outline future priorities for CRISPR enabled and omics guided rewiring, secretion and tolerance engineering, deployment of low cost/waste substrates, and standardized, scalable purification. These directions define a roadmap to robust, cost competitive SL manufacturing and clarify where recombinant hosts can complement or extend capabilities beyond Starmerella bombicola.
Indexed as
Identifiers
41528591What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.